Crimean-Congo haemorrhagic fever virus.
Journal
Nature reviews. Microbiology
ISSN: 1740-1534
Titre abrégé: Nat Rev Microbiol
Pays: England
ID NLM: 101190261
Informations de publication
Date de publication:
07 2023
07 2023
Historique:
accepted:
13
02
2023
medline:
16
6
2023
pubmed:
16
3
2023
entrez:
15
3
2023
Statut:
ppublish
Résumé
Crimean-Congo haemorrhagic fever (CCHF) is a severe tick-borne illness with a wide geographical distribution and case fatality rates of 30% or higher. Caused by infection with the CCHF virus (CCHFV), cases are reported throughout Africa, the Middle East, Asia and southern and eastern Europe. The expanding range of the Hyalomma tick vector is placing new populations at risk for CCHF, and no licensed vaccines or specific antivirals exist to treat CCHF. Furthermore, despite cases of CCHF being reported annually, the host and viral determinants of CCHFV pathogenesis are poorly understood. CCHFV can productively infect a multitude of animal species, yet only humans develop a severe illness. Within human populations, subclinical infections are underappreciated and may represent a substantial proportion of clinical outcomes. Compared with other members of the Bunyavirales order, CCHFV has a more complex genomic organization, with many viral proteins having unclear functions in viral pathogenesis. In recent years, improved animal models have led to increased insights into CCHFV pathogenesis, and several antivirals and vaccines for CCHFV have shown robust efficacy in preclinical models. Translation of these insights and candidate therapeutics to the clinic will hopefully reduce the morbidity and mortality caused by CCHFV.
Identifiants
pubmed: 36918725
doi: 10.1038/s41579-023-00871-9
pii: 10.1038/s41579-023-00871-9
pmc: PMC10013989
doi:
Substances chimiques
Vaccines
0
Antiviral Agents
0
Types de publication
Journal Article
Review
Research Support, N.I.H., Intramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
463-477Informations de copyright
© 2023. This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply.
Références
Simpson, D. I. et al. Congo virus: a hitherto undescribed virus occurring in Africa. I. Human isolations–clinical notes. East Afr. Med. J. 44, 86–92 (1967).
pubmed: 6040759
Casals, J. Antigenic similarity between the virus causing Crimean hemorrhagic fever and Congo virus. Proc. Soc. Exp. Biol. Med. 131, 233–236 (1969).
pubmed: 5770109
doi: 10.3181/00379727-131-33847
Messina, J. P. et al. The global distribution of Crimean-Congo hemorrhagic fever. Trans. R. Soc. Trop. Med. Hyg. 109, 503–513 (2015).
pubmed: 26142451
pmcid: 4501401
doi: 10.1093/trstmh/trv050
Gargili, A. et al. The role of ticks in the maintenance and transmission of Crimean-Congo hemorrhagic fever virus: a review of published field and laboratory studies. Antivir. Res. 144, 93–119 (2017).
pubmed: 28579441
doi: 10.1016/j.antiviral.2017.05.010
Lindeborg, M. et al. Migratory birds, ticks, and Crimean-Congo hemorrhagic fever virus. Emerg. Infect. Dis. 18, 2095–2097 (2012).
pubmed: 23171591
pmcid: 3557898
doi: 10.3201/eid1812.120718
Rainey, T., Occi, J. L., Robbins, R. G. & Egizi, A. Discovery of Haemaphysalis longicornis (Ixodida: Ixodidae) parasitizing a sheep in New Jersey, United States. J. Med. Entomol. 55, 757–759 (2018).
pubmed: 29471482
doi: 10.1093/jme/tjy006
Grandi, G. et al. First records of adult Hyalomma marginatum and H. rufipes ticks (Acari: Ixodidae) in Sweden. Ticks Tick Borne Dis. 11, 101403 (2020).
pubmed: 32037097
doi: 10.1016/j.ttbdis.2020.101403
Spengler, J. R., Bergeron, É. & Rollin, P. E. Seroepidemiological studies of Crimean-Congo hemorrhagic fever virus in domestic and wild animals. PLoS Negl. Trop. Dis. 10, e0004210 (2016).
pubmed: 26741652
pmcid: 4704823
doi: 10.1371/journal.pntd.0004210
Gordon, S. W., Linthicum, K. J. & Moulton, J. R. Transmission of Crimean-Congo hemorrhagic fever virus in two species of Hyalomma ticks from infected adults to cofeeding immature forms. Am. J. Trop. Med. Hyg. 48, 576–580 (1993).
pubmed: 8480867
doi: 10.4269/ajtmh.1993.48.576
Garrison, A. R. et al. ICTV virus taxonomy profile: Nairoviridae. J. Gen. Virol. 101, 798–799 (2020).
pubmed: 32840475
pmcid: 7641396
doi: 10.1099/jgv.0.001485
Burt, F. J., Spencer, D. C., Leman, P. A., Patterson, B. & Swanepoel, R. Investigation of tick-borne viruses as pathogens of humans in South Africa and evidence of Dugbe virus infection in a patient with prolonged thrombocytopenia. Epidemiol. Infect. 116, 353–361 (1996).
pubmed: 8666081
pmcid: 2271429
doi: 10.1017/S0950268800052687
Guu, T. S. Y., Zheng, W. & Tao, Y. J. in Viral Molecular Machines (eds Rossmann, M. G. & Rao, V. B.) 245–266 (Springer, 2012).
Carter, S. D. et al. Structure, function, and evolution of the Crimean-Congo hemorrhagic fever virus nucleocapsid protein. J. Virol. 86, 10914–10923 (2012).
pubmed: 22875964
pmcid: 3457148
doi: 10.1128/JVI.01555-12
Guo, Y. et al. Crimean–Congo hemorrhagic fever virus nucleoprotein reveals endonuclease activity in bunyaviruses. Proc. Natl Acad. Sci. USA 109, 5046–5051 (2012).
pubmed: 22421137
pmcid: 3324003
doi: 10.1073/pnas.1200808109
Jeeva, S., Cheng, E., Ganaie, S. S. & Mir, M. A. Crimean-Congo hemorrhagic fever virus nucleocapsid protein augments mRNA translation. J. Virol. https://doi.org/10.1128/jvi.00636-17 (2017).
doi: 10.1128/jvi.00636-17
pubmed: 28515298
pmcid: 5512247
Surtees, R. et al. Heat shock protein 70 family members interact with Crimean-Congo hemorrhagic fever virus and Hazara virus nucleocapsid proteins and perform a functional role in the nairovirus replication cycle. J. Virol. 90, 9305–9316 (2016).
pubmed: 27512070
pmcid: 5044845
doi: 10.1128/JVI.00661-16
Karlberg, H., Tan, Y.-J. & Mirazimi, A. Induction of caspase activation and cleavage of the viral nucleocapsid protein in different cell types during Crimean-Congo hemorrhagic fever virus infection. J. Biol. Chem. 286, 3227–3234 (2011).
pubmed: 21123175
doi: 10.1074/jbc.M110.149369
Karlberg, H., Tan, Y.-J. & Mirazimi, A. Crimean–Congo haemorrhagic fever replication interplays with regulation mechanisms of apoptosis. J. Gen. Virol. 96, 538–546 (2015).
pubmed: 25481756
doi: 10.1099/jgv.0.000011
Barnwal, B., Karlberg, H., Mirazimi, A. & Tan, Y.-J. The non-structural protein of Crimean-Congo hemorrhagic fever virus disrupts the mitochondrial membrane potential and induces apoptosis. J. Biol. Chem. 291, 582–592 (2016).
pubmed: 26574543
doi: 10.1074/jbc.M115.667436
Rodrigues, R., Paranhos-Baccalà, G., Vernet, G. & Peyrefitte, C. N. Crimean-Congo hemorrhagic fever virus-infected hepatocytes induce ER-stress and apoptosis crosstalk. PLoS ONE 7, e29712 (2012).
pubmed: 22238639
pmcid: 3253088
doi: 10.1371/journal.pone.0029712
Lindquist, M. E. et al. Exploring Crimean-Congo hemorrhagic fever virus-induced hepatic injury using antibody-mediated type I interferon blockade in mice. J. Virol. https://doi.org/10.1128/jvi.01083-18 (2018).
doi: 10.1128/jvi.01083-18
pubmed: 30111561
pmcid: 6189508
Engin, A., Aydin, H., Cinar, Z., Buyuktuna, S. A. & Bakir, M. Apoptosis and its relation with clinical course in patients with Crimean-Congo hemorrhagic fever. J. Med. Virol. 91, 1385–1393 (2019).
pubmed: 30905066
doi: 10.1002/jmv.25467
Güven, A. S. et al. Evaluation of serum perforin, caspase-3, sFasL and M-30 levels as apoptotic markers in children with Crimean-Congo hemorrhagic fever. Pediatr. Infect. Dis. J. 34, 208–213 (2015).
pubmed: 25170551
doi: 10.1097/INF.0000000000000530
Fuller, J. et al. Rescue of infectious recombinant Hazara nairovirus from cDNA reveals the nucleocapsid protein DQVD caspase cleavage motif performs an essential role other than cleavage. J. Virol. 93, e00616-19 (2019).
pubmed: 31118258
pmcid: 6639264
doi: 10.1128/JVI.00616-19
Wang, Y. et al. Structure of Crimean-Congo haemorraghic fever virus nucleoprotein: superhelical homo-oligomers and the role of caspase-3 cleavage. J. Virol. https://doi.org/10.1128/jvi.01627-12 (2012).
doi: 10.1128/jvi.01627-12
pubmed: 23269809
pmcid: 3503136
Salata, C. et al. The DEVD motif of Crimean-Congo hemorrhagic fever virus nucleoprotein is essential for viral replication in tick cells. Emerg. Microbes Infect. 7, 190 (2018).
pubmed: 30482897
pmcid: 6258742
doi: 10.1038/s41426-018-0192-0
Fuller, J. et al. Hazara nairovirus elicits differential induction of apoptosis and nucleocapsid protein cleavage in mammalian and tick cells. J. Gen. Virol. 100, 392–402 (2019).
pubmed: 30720418
doi: 10.1099/jgv.0.001211
Sanchez, A. J., Vincent, M. J. & Nichol, S. T. Characterization of the glycoproteins of Crimean-Congo hemorrhagic fever virus. J. Virol. https://doi.org/10.1128/jvi.76.14.7263-7275.2002 (2002).
doi: 10.1128/jvi.76.14.7263-7275.2002
pubmed: 12438572
pmcid: 136726
Sanchez, A. J., Vincent, M. J., Erickson, B. R. & Nichol, S. T. Crimean-Congo hemorrhagic fever virus glycoprotein precursor is cleaved by furin-like and SKI-1 proteases to generate a novel 38-kilodalton glycoprotein. J. Virol. https://doi.org/10.1128/jvi.80.1.514-525.2006 (2006).
doi: 10.1128/jvi.80.1.514-525.2006
pubmed: 16731927
pmcid: 1472584
Freitas, N. et al. The interplays between Crimean-Congo hemorrhagic fever virus (CCHFV) M segment-encoded accessory proteins and structural proteins promote virus assembly and infectivity. PLoS Pathog. 16, e1008850 (2020).
pubmed: 32956404
pmcid: 7529341
doi: 10.1371/journal.ppat.1008850
Hulswit, R. J. G., Paesen, G. C., Bowden, T. A. & Shi, X. Recent advances in Bunyavirus glycoprotein research: precursor processing, receptor binding and structure. Viruses https://doi.org/10.3390/v13020353 (2021).
doi: 10.3390/v13020353
pubmed: 33672327
pmcid: 7926653
Garrison, A. R. et al. Crimean-Congo hemorrhagic fever virus utilizes a clathrin- and early endosome-dependent entry pathway. Virology 444, 45–54 (2013).
pubmed: 23791227
doi: 10.1016/j.virol.2013.05.030
Bertolotti-Ciarlet, A. et al. Cellular localization and antigenic characterization of Crimean-Congo hemorrhagic fever virus glycoproteins. J. Virol. 79, 6152–6161 (2005).
pubmed: 15858000
pmcid: 1091677
doi: 10.1128/JVI.79.10.6152-6161.2005
Erickson, B. R., Deyde, V., Sanchez, A. J., Vincent, M. J. & Nichol, S. T. N-linked glycosylation of Gn (but not Gc) is important for Crimean Congo hemorrhagic fever virus glycoprotein localization and transport. Virology https://doi.org/10.1016/j.virol.2006.11.023 (2007).
doi: 10.1016/j.virol.2006.11.023
pubmed: 17197010
Vincent, M. J. et al. Crimean-Congo hemorrhagic fever virus glycoprotein proteolytic processing by subtilase SKI-1. J. Virol. https://doi.org/10.1128/jvi.77.16.8640-8649.2003 (2003).
doi: 10.1128/jvi.77.16.8640-8649.2003
pubmed: 14645585
pmcid: 296043
Bente, D. A. et al. Crimean-Congo hemorrhagic fever: history, epidemiology, pathogenesis, clinical syndrome and genetic diversity. Antivir. Res. 100, 159–189 (2013).
pubmed: 23906741
doi: 10.1016/j.antiviral.2013.07.006
Deyde, V. M., Khristova, M. L., Rollin, P. E., Ksiazek, T. G. & Nichol, S. T. Crimean-Congo hemorrhagic fever virus genomics and global diversity. J. Virol. https://doi.org/10.1128/jvi.00752-06 (2006).
doi: 10.1128/jvi.00752-06
pubmed: 16912331
pmcid: 1563879
Yang, Z.-y et al. Identification of the Ebola virus glycoprotein as the main viral determinant of vascular cell cytotoxicity and injury. Nat. Med. 6, 886–889 (2000).
pubmed: 10932225
doi: 10.1038/78654
Francica, J. R., Matukonis, M. K. & Bates, P. Requirements for cell rounding and surface protein down-regulation by Ebola virus glycoprotein. Virology 383, 237–247 (2009).
pubmed: 19013626
doi: 10.1016/j.virol.2008.10.029
Golden, J. W. et al. GP38-targeting monoclonal antibodies protect adult mice against lethal Crimean-Congo hemorrhagic fever virus infection. Sci. Adv. 5, eaaw9535 (2019).
pubmed: 31309159
pmcid: 6620094
doi: 10.1126/sciadv.aaw9535
Welch, S. R. et al. The Crimean-Congo hemorrhagic fever virus NSm protein is dispensable for growth in vitro and disease in Ifnar
pubmed: 32455700
pmcid: 7285326
doi: 10.3390/microorganisms8050775
Xia, H. et al. Transstadial transmission and long-term association of Crimean-Congo hemorrhagic fever virus in ticks shapes genome plasticity. Sci. Rep. 6, 35819 (2016).
pubmed: 27775001
pmcid: 5075774
doi: 10.1038/srep35819
Hawman, D. W. et al. Immunocompetent mouse model for Crimean-Congo hemorrhagic fever virus. eLife 10, e63906 (2021).
pubmed: 33416494
pmcid: 7811403
doi: 10.7554/eLife.63906
Honig, J. E., Osborne, J. C. & Nichol, S. T. Crimean-Congo hemorrhagic fever virus genome L RNA segment and encoded protein. Virology https://doi.org/10.1016/j.virol.2003.09.042 (2004).
doi: 10.1016/j.virol.2003.09.042
pubmed: 15033562
Holm, T. et al. Biochemical and structural studies reveal differences and commonalities among cap-snatching endonucleases from segmented negative-strand RNA viruses. J. Biol. Chem. 293, 19686–19698 (2018).
pubmed: 30348898
pmcid: 6314124
doi: 10.1074/jbc.RA118.004373
Honig, J. E., Osborne, J. C. & Nichol, S. T. Crimean–Congo hemorrhagic fever virus genome L RNA segment and encoded protein. Virology 321, 29–35 (2004).
pubmed: 15033562
doi: 10.1016/j.virol.2003.09.042
Spengler, J. R. et al. RIG-I mediates an antiviral response to Crimean-Congo hemorrhagic fever virus. J. Virol. 89, 10219–10229 (2015).
pubmed: 26223644
pmcid: 4580164
doi: 10.1128/JVI.01643-15
Scholte, F. E. M. et al. Crimean-Congo hemorrhagic fever virus suppresses innate immune responses via a ubiquitin and ISG15 specific protease. Cell Rep. 20, 2396–2407 (2017).
pubmed: 28877473
pmcid: 5616139
doi: 10.1016/j.celrep.2017.08.040
Perng, Y.-C. & Lenschow, D. J. ISG15 in antiviral immunity and beyond. Nat. Rev. Microbiol. 16, 423–439 (2018).
pubmed: 29769653
pmcid: 7097117
doi: 10.1038/s41579-018-0020-5
Scholte, F. E. M. et al. Stable occupancy of the Crimean-Congo hemorrhagic fever virus-encoded deubiquitinase blocks viral infection. mBio https://doi.org/10.1128/mBio.01065-19 (2019).
doi: 10.1128/mBio.01065-19
pubmed: 31337717
pmcid: 6650548
Devignot, S., Kromer, T., Mirazimi, A. & Weber, F. ISG15 overexpression compensates the defect of Crimean-Congo hemorrhagic fever virus polymerase bearing a protease-inactive ovarian tumor domain. PLoS Negl. Trop. Dis. 14, e0008610 (2020).
pubmed: 32931521
pmcid: 7518590
doi: 10.1371/journal.pntd.0008610
Capodagli, G. C., Deaton, M. K., Baker, E. A., Lumpkin, R. J. & Pegan, S. D. Diversity of ubiquitin and ISG15 specificity among nairoviruses’ viral ovarian tumor domain proteases. J. Virol. 87, 3815–3827 (2013).
pubmed: 23345508
pmcid: 3624237
doi: 10.1128/JVI.03252-12
Dzimianski, J. V. et al. Probing the impact of nairovirus genomic diversity on viral ovarian tumor domain protease (vOTU) structure and deubiquitinase activity. PLoS Pathog. 15, e1007515 (2019).
pubmed: 30629698
pmcid: 6343935
doi: 10.1371/journal.ppat.1007515
Leventhal, S. S., Wilson, D., Feldmann, H. & Hawman, D. W. A look into Bunyavirales genomes: functions of non-structural (NS) proteins. Viruses 13, 314 (2021).
pubmed: 33670641
pmcid: 7922539
doi: 10.3390/v13020314
Zhou, Z. et al. Reassortment and migration analysis of Crimean–Congo haemorrhagic fever virus. J. Gen. Virol. 94, 2536–2548 (2013).
pubmed: 23939975
doi: 10.1099/vir.0.056374-0
Balinandi, S. et al. Clinical and molecular epidemiology of Crimean-Congo hemorrhagic fever in humans in Uganda, 2013–2019. Am. J. Trop. Med. Hyg. 106, 88–98 (2021).
pubmed: 34662872
pmcid: 8733546
doi: 10.4269/ajtmh.21-0685
Wampande, E. M. et al. Phylogenetic characterization of Crimean-Congo hemorrhagic fever virus detected in African blue ticks feeding on cattle in a Ugandan abattoir. Microorganisms https://doi.org/10.3390/microorganisms9020438 (2021).
doi: 10.3390/microorganisms9020438
pubmed: 33672497
pmcid: 7923759
Estrada-Peña, A. et al. Crimean-Congo hemorrhagic fever virus in ticks, southwestern Europe, 2010. Emerg. Infect. Dis. 18, 179–180 (2012).
pubmed: 22261502
pmcid: 3310114
doi: 10.3201/eid1801.111040
Hewson, R. et al. Evidence of segment reassortment in Crimean-Congo haemorrhagic fever virus. J. Gen. Virol. https://doi.org/10.1099/vir.0.80121-0 (2004).
doi: 10.1099/vir.0.80121-0
pubmed: 15448369
Midilli, K. et al. The first clinical case due to AP92 like strain of Crimean-Congo hemorrhagic fever virus and a field survey. BMC Infect. Dis. 9, 90 (2009).
pubmed: 19515251
pmcid: 2700115
doi: 10.1186/1471-2334-9-90
Gunes, T. et al. Crimean-Congo hemorrhagic fever virus in high-risk population, Turkey. Emerg. Infect. Dis. 15, 461–464 (2009).
pubmed: 19239765
pmcid: 2681111
doi: 10.3201/eid1503.080687
Msimang, V. et al. Risk factors associated with exposure to Crimean-Congo haemorrhagic fever virus in animal workers and cattle, and molecular detection in ticks, South Africa. PLoS Negl. Trop. Dis. 15, e0009384 (2021).
pubmed: 34048430
pmcid: 8162673
doi: 10.1371/journal.pntd.0009384
Elaldi, N. et al. Efficacy of oral ribavirin treatment in Crimean-Congo haemorrhagic fever: a quasi-experimental study from Turkey. J. Infect. 58, 238–244 (2009).
pubmed: 19246100
doi: 10.1016/j.jinf.2009.01.014
Hoogstraal, H. Review article: the epidemiology of tick-borne Crimean-Congo hemorrhagic fever in Asia, Europe, and Africa. J. Med. Entomol. 15, 307–417 (1979).
pubmed: 113533
doi: 10.1093/jmedent/15.4.307
Mallhi, T. H., Khan, Y. H., Sarriff, A. & Khan, A. H. Crimean-Congo haemorrhagic fever virus and Eid-ul-Adha festival in Pakistan. Lancet Infect. Dis. 16, 1332–1333 (2016).
pubmed: 27998596
doi: 10.1016/S1473-3099(16)30453-4
Leblebicioglu, H. et al. Consensus report: preventive measures for Crimean-Congo hemorrhagic fever during Eid-al-Adha festival. Int. J. Infect. Dis. 38, 9–15 (2015).
pubmed: 26183413
doi: 10.1016/j.ijid.2015.06.029
Leblebicioglu, H. et al. Healthcare-associated Crimean-Congo haemorrhagic fever in Turkey, 2002–2014: a multicentre retrospective cross-sectional study. Clin. Microbiol. Infect. 22, 387.e1–387.e4 (2016).
pubmed: 26806137
doi: 10.1016/j.cmi.2015.11.024
Khan, J. A. et al. Crimean Congo-haemorrhagic fever treated with oral ribavirin. Lancet 346, 472–475 (1995).
pubmed: 7637481
doi: 10.1016/S0140-6736(95)91323-8
Pshenichnaya, N. Y. & Nenadskaya, S. A. Probable Crimean-Congo hemorrhagic fever virus transmission occurred after aerosol-generating medical procedures in Russia: nosocomial cluster. Int. J. Infect. Dis. 33, 120–122 (2015).
pubmed: 25576827
doi: 10.1016/j.ijid.2014.12.047
Pshenichnaya, N. Y., Sydenko, I. S., Klinovaya, E. P., Romanova, E. B. & Zhuravlev, A. S. Possible sexual transmission of Crimean-Congo hemorrhagic fever. Int. J. Infect. Dis. 45, 109–111 (2016).
pubmed: 26972040
doi: 10.1016/j.ijid.2016.02.1008
Rugarabamu, S. et al. Forty-two years of responding to Ebola virus outbreaks in sub-Saharan Africa: a review. BMJ Glob. Health 5, e001955 (2020).
pubmed: 32201623
pmcid: 7061886
doi: 10.1136/bmjgh-2019-001955
Kar, S. et al. Crimean-Congo hemorrhagic fever virus in tortoises and Hyalomma aegyptium ticks in East Thrace, Turkey: potential of a cryptic transmission cycle. Parasit. Vectors 13, 201 (2020).
pubmed: 32307010
pmcid: 7168965
doi: 10.1186/s13071-020-04074-6
Ergonul, O. Crimean-Congo haemorrhagic fever. Lancet Infect. Dis. https://doi.org/10.1016/s1473-3099(06)70435-2 (2006).
doi: 10.1016/s1473-3099(06)70435-2
pubmed: 16554245
pmcid: 7185836
Swanepoel, R. et al. The clinical pathology of Crimean-Congo hemorrhagic fever. Rev. Infect. Dis. 11, S794–S800 (1989).
pubmed: 2749111
doi: 10.1093/clinids/11.Supplement_4.S794
Swanepoel, R. et al. Epidemiologic and clinical features of Crimean-Congo hemorrhagic fever in southern Africa. Am. J. Trop. Med. Hyg. 36, 120–132 (1987).
pubmed: 3101525
doi: 10.4269/ajtmh.1987.36.120
Bakir, M. et al. Crimean-Congo haemorrhagic fever outbreak in Middle Anatolia: a multicentre study of clinical features and outcome measures. J. Med. Microbiol. 54, 385–389 (2005).
pubmed: 15770025
doi: 10.1099/jmm.0.45865-0
Ergonul, O., Celikbas, A., Baykam, N., Eren, S. & Dokuzoguz, B. Analysis of risk-factors among patients with Crimean-Congo haemorrhagic fever virus infection: severity criteria revisited. Clin. Microbiol. Infect. 12, 551–554 (2006).
pubmed: 16700704
doi: 10.1111/j.1469-0691.2006.01445.x
Çevik, M. A. et al. Clinical and laboratory features of Crimean-Congo hemorrhagic fever: predictors of fatality. Int. J. Infect. Dis. 12, 374–379 (2008).
pubmed: 18063402
doi: 10.1016/j.ijid.2007.09.010
Kleib, A. S. et al. Crimean-Congo hemorrhagic fever with acute subdural hematoma, Mauritania, 2012. Emerg. Infect. Dis. 22, 1305–1306 (2016).
pubmed: 27315138
pmcid: 4918161
doi: 10.3201/eid2207.151782
Hatami, H., Qaderi, S. & Omid, A. M. Investigation of Crimean-Congo hemorrhagic fever in patients admitted in Antani Hospital, Kabul, Afghanistan, 2017–2018. Int. J. Prev. Med. 10, 117 (2019).
pubmed: 31367281
pmcid: 6639848
doi: 10.4103/ijpvm.IJPVM_391_18
Qaderi, S., Hatami, H., Omid, A. M. & Sayad, J. Vaginal bleeding as a sign of Crimean-Congo hemorrhagic fever infection: a case report. J. Med. Case Rep. 16, 76 (2022).
pubmed: 35189976
pmcid: 8862576
doi: 10.1186/s13256-022-03303-z
Bastug, A. et al. Crimean-Congo hemorrhagic fever: prognostic factors and the association of leukocyte counts with mortality. Jpn J. Infect. Dis. 69, 51–55 (2016).
pubmed: 26073733
doi: 10.7883/yoken.JJID.2014.566
Aksoy, F., Yilmaz, G., Kaya, S., Karahan, S. C. & Koksal, I. The prognostic importance of platelet indices in patients with Crimean-Congo hemorrhagic fever. Open Forum Infect. Dis. 4 (Suppl. 1), S352–S353 (2017).
pmcid: 5631392
doi: 10.1093/ofid/ofx163.850
Dokuzoguz, B. et al. Severity scoring index for Crimean-Congo hemorrhagic fever and the impact of ribavirin and corticosteroids on fatality. Clin. Infect. Dis. 57, 1270–1274 (2013).
pubmed: 23946218
doi: 10.1093/cid/cit527
Papa, A. et al. Cytokines as biomarkers of Crimean-Congo hemorrhagic fever. J. Med. Virol. 88, 21–27 (2015).
pubmed: 26118413
doi: 10.1002/jmv.24312
Saksida, A. et al. Interacting roles of immune mechanisms and viral load in the pathogenesis of Crimean-Congo hemorrhagic fever. Clin. Vaccin. Immunol. 17, 1086–1093 (2010).
doi: 10.1128/CVI.00530-09
Ergonul, O., Tuncbilek, S., Baykam, N., Celikbas, A. & Dokuzoguz, B. Evaluation of serum levels of interleukin (IL)-6, IL-10, and tumor necrosis factor-α in patients with Crimean-Congo hemorrhagic fever. J. Infect. Dis. 193, 941–944 (2006).
pubmed: 16518755
doi: 10.1086/500836
Papa, A. et al. A case of Crimean-Congo haemorrhagic fever in Greece, June 2008. Eurosurveillance 13, 18952 (2008).
pubmed: 18761893
doi: 10.2807/ese.13.33.18952-en
Jamil, B. et al. Crimean-Congo hemorrhagic fever: experience at a tertiary care hospital in Karachi, Pakistan. Trans. R. Soc. Trop. Med. Hyg. 99, 577–584 (2005).
pubmed: 15935414
doi: 10.1016/j.trstmh.2005.03.002
Ergönül, Ö. et al. Characteristics of patients with Crimean-Congo hemorrhagic fever in a recent outbreak in Turkey and impact of oral ribavirin therapy. Clin. Infect. Dis. 39, 284–287 (2004).
pubmed: 15307042
doi: 10.1086/422000
Shepherd, A. J., Swanepoel, R. & Leman, P. A. Antibody response in Crimean-Congo hemorrhagic fever. Rev. Infect. Dis. 11, S801–S806 (1989).
pubmed: 2501854
doi: 10.1093/clinids/11.Supplement_4.S801
Goedhals, D., Paweska, J. T. & Burt, F. J. Long-lived CD8
pubmed: 29261651
pmcid: 5752039
doi: 10.1371/journal.pntd.0006149
Çevik, M. A. et al. Viral load as a predictor of outcome in Crimean-Congo hemorrhagic fever. Clin. Infect. Dis. 45, e96–e100 (2007).
pubmed: 17806044
doi: 10.1086/521244
Duh, D. et al. Viral load as predictor of Crimean-Congo hemorrhagic fever outcome. Emerg. Infect. Dis. 13, 1769–1772 (2007).
pubmed: 18217568
pmcid: 3375790
doi: 10.3201/eid1311.070222
Papa, A. et al. Cytokine levels in Crimean-Congo hemorrhagic fever. J. Clin. Virol. 36, 272–276 (2006).
pubmed: 16765637
doi: 10.1016/j.jcv.2006.04.007
Ergunay, K. et al. Antibody responses and viral load in patients with Crimean-Congo hemorrhagic fever: a comprehensive analysis during the early stages of the infection. Diagn. Microbiol. Infect. Dis. 79, 31–36 (2014).
pubmed: 24630756
doi: 10.1016/j.diagmicrobio.2013.12.015
Kaya, S. et al. Sequential determination of serum viral titers, virus-specific IgG antibodies, and TNF-α, IL-6, IL-10, and IFN-γ levels in patients with Crimean-Congo hemorrhagic fever. BMC Infect. Dis. 14, 416 (2014).
pubmed: 25066751
pmcid: 4133611
doi: 10.1186/1471-2334-14-416
Burt, F. J., Leman, P. A., Abbott, J. C. & Swanepoel, R. Serodiagnosis of Crimean-Congo haemorrhagic fever. Epidemiol. Infect. 113, 551–562 (1994).
pubmed: 7995364
pmcid: 2271329
doi: 10.1017/S0950268800068576
Papadopoulos, O. T. & Koptopoulos, G. Crimean-Congo hemorrhagic fever (CCHF) in Greece: isolation of the virus from Rhipicephalus bursa ticks and a preliminary serological survey. Zentbl. Bakteriol. Hyg. Abt. 1, 189–193 (1980).
Papa, A. et al. Factors associated with IgG positivity to Crimean-Congo hemorrhagic fever virus in the area with the highest seroprevalence in Greece. Ticks Tick Borne Dis. 4, 417–420 (2013).
pubmed: 23831367
doi: 10.1016/j.ttbdis.2013.04.003
Papa, A. et al. A novel AP92-like Crimean-Congo hemorrhagic fever virus strain, Greece. Ticks Tick Borne Dis. 5, 590–593 (2014).
pubmed: 24953797
doi: 10.1016/j.ttbdis.2014.04.008
Arslan, S. & Engin, A. Relationship between NF-κB1 and NF-κBIA genetic polymorphisms and Crimean-Congo hemorrhagic fever. Scand. J. Infect. Dis. 44, 138–143 (2012).
pubmed: 22066734
doi: 10.3109/00365548.2011.623313
Arslan, S., Engin, A., Özbilüm, N. & Bakır, M. Toll-like receptor 7 Gln11Leu, c.4-151A/G, and +1817G/T polymorphisms in Crimean Congo hemorrhagic fever. J. Med. Virol. 87, 1090–1095 (2015).
pubmed: 25879168
doi: 10.1002/jmv.24174
Elaldi, N. et al. Relationship between IFNA1, IFNA5, IFNA10, and IFNA17 gene polymorphisms and Crimean-Congo hemorrhagic fever prognosis in a Turkish population range. J. Med. Virol. 88, 1159–1167 (2016).
pubmed: 26694082
doi: 10.1002/jmv.24456
Engin, A. et al. Toll-like receptor 8 and 9 polymorphisms in Crimean-Congo hemorrhagic fever. Microbes Infect. 12, 1071–1078 (2010).
pubmed: 20674764
doi: 10.1016/j.micinf.2010.07.012
Kızıldağ, S., Arslan, S., Özbilüm, N., Engin, A. & Bakır, M. Effect of TLR10 (2322A/G, 720A/C, and 992T/A) polymorphisms on the pathogenesis of Crimean Congo hemorrhagic fever disease. J. Med. Virol. 90, 19–25 (2018).
pubmed: 28843003
doi: 10.1002/jmv.24924
Akıncı, E., Bodur, H., Muşabak, U. & Sağkan, R. I. The relationship between the human leukocyte antigen system and Crimean-Congo hemorrhagic fever in the Turkish population. Int. J. Infect. Dis. 17, e1038–e1041 (2013).
pubmed: 23911239
doi: 10.1016/j.ijid.2013.06.005
Bodur, H., Akinci, E., Ascioglu, S., Öngürü, P. & Uyar, Y. Subclinical infections with Crimean-Congo hemorrhagic fever virus, Turkey. Emerg. Infect. Dis. 18, 640–642 (2012).
pubmed: 22469474
pmcid: 3309668
doi: 10.3201/eid1804.111374
Tignor, G. H. & Hanham, C. A. Ribavirin efficacy in an in vivo model of Crimean-Congo hemorrhagic fever virus (CCHF) infection. Antivir. Res. 22, 309–325 (1993).
pubmed: 8279818
doi: 10.1016/0166-3542(93)90040-P
Bente, D. A. et al. Pathogenesis and immune response of Crimean-Congo hemorrhagic fever virus in a STAT-1 knockout mouse model. J. Virol. 84, 11089–11100 (2010).
pubmed: 20739514
pmcid: 2953203
doi: 10.1128/JVI.01383-10
Bereczky, S. et al. Crimean–Congo hemorrhagic fever virus infection is lethal for adult type I interferon receptor-knockout mice. J. Gen. Virol. 91, 1473–1477 (2010).
pubmed: 20164263
doi: 10.1099/vir.0.019034-0
Ranadheera, C. et al. Characterization of a novel STAT 2 knock-out hamster model of Crimean-Congo hemorrhagic fever virus pathogenesis. Sci. Rep. 10, 12378 (2020).
pubmed: 32704046
pmcid: 7378551
doi: 10.1038/s41598-020-69054-3
Zivcec, M. et al. Lethal Crimean-Congo hemorrhagic fever virus infection in interferon α/β receptor knockout mice is associated with high viral loads, proinflammatory responses, and coagulopathy. J. Infect. Dis. 207, 1909–1921 (2013).
pubmed: 23417661
pmcid: 3654741
doi: 10.1093/infdis/jit061
Oestereich, L. et al. Evaluation of antiviral efficacy of ribavirin, arbidol, and T-705 (favipiravir) in a mouse model for Crimean-Congo hemorrhagic fever. PLoS Negl. Trop. Dis. 8, e2804 (2014).
pubmed: 24786461
pmcid: 4006714
doi: 10.1371/journal.pntd.0002804
Welch, S. R. et al. Identification of 2′-deoxy-2′-fluorocytidine as a potent inhibitor of Crimean-Congo hemorrhagic fever virus replication using a recombinant fluorescent reporter virus. Antivir. Res. 147, 91–99 (2017).
pubmed: 29024765
doi: 10.1016/j.antiviral.2017.10.008
Hawman, D. W. et al. Favipiravir (T-705) but not ribavirin is effective against two distinct strains of Crimean-Congo hemorrhagic fever virus in mice. Antivir. Res. 157, 18–26 (2018).
pubmed: 29936152
doi: 10.1016/j.antiviral.2018.06.013
Fels, J. M. et al. Protective neutralizing antibodies from human survivors of Crimean-Congo hemorrhagic fever. Cell 184, 3486–3501.e21 (2021).
pubmed: 34077751
pmcid: 8559771
doi: 10.1016/j.cell.2021.05.001
Tipih, T. & Burt, F. J. Crimean-Congo hemorrhagic fever virus: advances in vaccine development. Biores. Open Access 9, 137–150 (2020).
pubmed: 32461819
pmcid: 7247048
doi: 10.1089/biores.2019.0057
Golden, J. W. et al. The host inflammatory response contributes to disease severity in Crimean-Congo hemorrhagic fever virus infected mice. PLoS Pathog. 18, e1010485 (2022).
pubmed: 35587473
pmcid: 9119488
doi: 10.1371/journal.ppat.1010485
Hawman, D. W. et al. A Crimean-Congo hemorrhagic fever mouse model recapitulating human convalescence. J. Virol. https://doi.org/10.1128/JVI.00554-19 (2019).
doi: 10.1128/JVI.00554-19
pubmed: 31292241
pmcid: 6714788
Welch, S. R. et al. Fluorescent Crimean-Congo hemorrhagic fever virus illuminates tissue tropism patterns and identifies early mononuclear phagocytic cell targets in Ifnar
pubmed: 31790513
pmcid: 6984736
doi: 10.1371/journal.ppat.1008183
Zampieri, C. A., Sullivan, N. J. & Nabel, G. J. Immunopathology of highly virulent pathogens: insights from Ebola virus. Nat. Immunol. 8, 1159–1164 (2007).
pubmed: 17952040
pmcid: 7097212
doi: 10.1038/ni1519
Basler, C. F. Molecular pathogenesis of viral hemorrhagic fever. Semin. Immunopathol. 39, 551–561 (2017).
pubmed: 28555386
pmcid: 6436832
doi: 10.1007/s00281-017-0637-x
Hawman, D. W. et al. T-cells and interferon gamma are necessary for survival following Crimean-Congo hemorrhagic fever virus infection in mice. Microorganisms https://doi.org/10.3390/microorganisms9020279 (2021).
doi: 10.3390/microorganisms9020279
pubmed: 34065996
pmcid: 8151856
Spengler, J. R. et al. Crimean-Congo hemorrhagic fever in humanized mice reveals glial cells as primary targets of neurological infection. J. Infect. Dis. https://doi.org/10.1093/infdis/jix215 (2017).
doi: 10.1093/infdis/jix215
pubmed: 29087482
pmcid: 5853858
Zivcec, M., Spiropoulou, C. F. & Spengler, J. R. The use of mice lacking type I or both type I and type II interferon responses in research on hemorrhagic fever viruses. Part 2: vaccine efficacy studies. Antivir. Res. 174, 104702 (2020).
pubmed: 31982149
doi: 10.1016/j.antiviral.2019.104702
Clarke, E. C. & Bradfute, S. B. The use of mice lacking type I or both type I and type II interferon responses in research on hemorrhagic fever viruses. Part 1: potential effects on adaptive immunity and response to vaccination. Antivir. Res. 174, 104703 (2020).
pubmed: 31932041
doi: 10.1016/j.antiviral.2019.104703
Monsalve-Arteaga, L. et al. Seroprevalence of Crimean-Congo hemorrhagic fever in humans in the World Health Organization European region: a systematic review. PLoS Negl. Trop. Dis. 14, e0008094 (2020).
pubmed: 32119682
pmcid: 7067482
doi: 10.1371/journal.pntd.0008094
Yagci-Caglayik, D., Korukluoglu, G. & Uyar, Y. Seroprevalence and risk factors of Crimean–Congo hemorrhagic fever in selected seven provinces in Turkey. J. Med. Virol. 86, 306–314 (2014).
pubmed: 24037814
doi: 10.1002/jmv.23699
Bower, H. et al. Detection of Crimean-Congo haemorrhagic fever cases in a severe undifferentiated febrile illness outbreak in the Federal Republic of Sudan: a retrospective epidemiological and diagnostic cohort study. PLoS Negl. Trop. Dis. 13, e0007571 (2019).
pubmed: 31291242
pmcid: 6645580
doi: 10.1371/journal.pntd.0007571
Chinikar, S. et al. Geographical distribution and surveillance of Crimean-Congo hemorrhagic fever in Iran. Vector Borne Zoonotic Dis. 10, 705–708 (2010).
pubmed: 20854025
doi: 10.1089/vbz.2009.0247
Haddock, E. et al. A cynomolgus macaque model for Crimean-Congo haemorrhagic fever. Nat. Microbiol. 3, 556–562 (2018).
pubmed: 29632370
pmcid: 6717652
doi: 10.1038/s41564-018-0141-7
Hawman, D. W. et al. Efficacy of favipiravir (T-705) against Crimean-Congo hemorrhagic fever virus infection in cynomolgus macaques. Antivir. Res. https://doi.org/10.1016/j.antiviral.2020.104858 (2020).
doi: 10.1016/j.antiviral.2020.104858
pubmed: 32645335
Cross, R. W. et al. Crimean-Congo hemorrhagic fever virus strains Hoti and Afghanistan cause viremia and mild clinical disease in cynomolgus monkeys. PLoS Negl. Trop. Dis. 14, e0008637 (2020).
pubmed: 32790668
pmcid: 7447009
doi: 10.1371/journal.pntd.0008637
Smith, D. R. et al. Persistent Crimean-Congo hemorrhagic fever virus infection in the testes and within granulomas of non-human primates with latent tuberculosis. PLoS Pathog. 15, e1008050 (2019).
pubmed: 31557262
pmcid: 6782109
doi: 10.1371/journal.ppat.1008050
Coffey, L. L., Forrester, N., Tsetsarkin, K., Vasilakis, N. & Weaver, S. C. Factors shaping the adaptive landscape for arboviruses: implications for the emergence of disease. Future Microbiol. 8, 155–176 (2013).
pubmed: 23374123
doi: 10.2217/fmb.12.139
Hua, B. L. et al. A single mutation in Crimean-Congo hemorrhagic fever virus discovered in ticks impairs infectivity in human cells. eLife 9, e50999 (2020).
pubmed: 33084573
pmcid: 7652417
doi: 10.7554/eLife.50999
Ergonul, O. Debate (see Elaldi N et al., Efficacy of oral ribavirin treatment in Crimean-Congo haemorrhagic fever: a quasi-experimental study from Turkey. Journal of Infection 2009; 58: 238–244): biases and misinterpretation in the assessment of the efficacy of oral ribavirin in the treatment of Crimean–Congo hemorrhagic fever. J. Infect. 59, 284–286 (2009).
pubmed: 19699762
doi: 10.1016/j.jinf.2009.08.006
Ergonul, O. Evidence supports ribavirin use in Crimean-Congo hemorrhagic fever. Int. J. Infect. Dis. 29, 296 (2014).
pubmed: 25461237
doi: 10.1016/j.ijid.2014.08.016
Ceylan, B., Calica, A., Ak, O., Akkoyunlu, Y. & Turhan, V. Ribavirin is not effective against Crimean-Congo hemorrhagic fever: observations from the Turkish experience. Int. J. Infect. Dis. 17, e799–e801 (2013).
pubmed: 23773242
pmcid: 7110843
doi: 10.1016/j.ijid.2013.02.030
Espy, N. et al. Ribavirin had demonstrable effects on the Crimean-Congo hemorrhagic fever virus (CCHFV) population and load in a patient with CCHF infection. J. Infect. Dis. 217, 1952–1956 (2018).
pubmed: 29584885
doi: 10.1093/infdis/jiy163
Koksal, I. et al. The efficacy of ribavirin in the treatment of Crimean-Congo hemorrhagic fever in eastern Black Sea region in Turkey. J. Clin. Virol. 47, 65–68 (2010).
pubmed: 19962342
doi: 10.1016/j.jcv.2009.11.007
Tasdelen Fisgin, N., Ergonul, O., Doganci, L. & Tulek, N. The role of ribavirin in the therapy of Crimean-Congo hemorrhagic fever: early use is promising. Eur. J. Clin. Microbiol. Infect. Dis. 28, 929–933 (2009).
pubmed: 19301047
doi: 10.1007/s10096-009-0728-2
Ascioglu, S., Leblebicioglu, H., Vahaboglu, H. & Chan, K. A. Ribavirin for patients with Crimean–Congo haemorrhagic fever: a systematic review and meta-analysis. J. Antimicrob. Chemother. 66, 1215–1222 (2011).
pubmed: 21482564
doi: 10.1093/jac/dkr136
Johnson, S. et al. Ribavirin for treating Crimean Congo haemorrhagic fever. Cochrane Database Syst. Rev. 6, CD012713 (2018).
pubmed: 29869797
Arab-Bafrani, Z. et al. Identification of the crucial parameters regarding the efficacy of ribavirin therapy in Crimean–Congo haemorrhagic fever (CCHF) patients: a systematic review and meta-analysis. J. Antimicrob. Chemother. 74, 3432–3439 (2019).
pubmed: 31369086
doi: 10.1093/jac/dkz328
Wang, Q. et al. In vitro and in vivo efficacy of a novel nucleoside analog H44 against Crimean–Congo hemorrhagic fever virus. Antivir. Res. 199, 105273 (2022).
pubmed: 35257725
doi: 10.1016/j.antiviral.2022.105273
Büyüktuna, S. A. et al. [COVID-19 co-infection in a patient with Crimean Congo hemorrhagic fever: a case report]. Mikrobiyol. Bul. 55, 445–451 (2021).
pubmed: 34416809
doi: 10.5578/mb.20219813
Jayk Bernal, A. et al. Molnupiravir for oral treatment of Covid-19 in nonhospitalized patients. N. Engl. J. Med. 386, 509–520 (2021).
pubmed: 34914868
doi: 10.1056/NEJMoa2116044
Vanderlinden, E. et al. Distinct effects of T-705 (favipiravir) and ribavirin on influenza virus replication and viral RNA synthesis. Antimicrob. Agents Chemother. 60, 6679–6691 (2016).
pubmed: 27572398
pmcid: 5075073
doi: 10.1128/AAC.01156-16
Tampere, M. et al. Novel broad-spectrum antiviral inhibitors targeting host factors essential for replication of pathogenic RNA viruses. Viruses 12, 1423 (2020).
pubmed: 33322045
pmcid: 7762994
doi: 10.3390/v12121423
Fabara, S. P. et al. Crimean-Congo hemorrhagic fever beyond ribavirin: a systematic review. Cureus 13, e17842 (2021).
pubmed: 34557373
pmcid: 8450012
Keshtkar-Jahromi, M. et al. Crimean-Congo hemorrhagic fever: current and future prospects of vaccines and therapies. Antivir. Res. 90, 85–92 (2011).
pubmed: 21362441
doi: 10.1016/j.antiviral.2011.02.010
Zivcec, M. et al. Identification of broadly neutralizing monoclonal antibodies against Crimean-Congo hemorrhagic fever virus. Antivir. Res. 146, 112–120 (2017).
pubmed: 28842265
doi: 10.1016/j.antiviral.2017.08.014
Sharifi-Mood, B. et al. Efficacy of high-dose methylprednisolone in patients with Crimean-Congo haemorrhagic fever and severe thrombocytopenia. Trop. Doct. 43, 49–53 (2013).
pubmed: 23796671
doi: 10.1177/0049475513486642
Li, P., Zheng, Y. & Chen, X. Drugs for autoimmune inflammatory diseases: from small molecule compounds to anti-TNF biologics. Front. Pharmacol. https://doi.org/10.3389/fphar.2017.00460 (2017).
doi: 10.3389/fphar.2017.00460
pubmed: 29403377
pmcid: 5743740
Kopf, M., Bachmann, M. F. & Marsland, B. J. Averting inflammation by targeting the cytokine environment. Nat. Rev. Drug Discov. 9, 703–718 (2010).
pubmed: 20811382
doi: 10.1038/nrd2805
Kumar, B., Manjunathachar, H. V. & Ghosh, S. A review on Hyalomma species infestations on human and animals and progress on management strategies. Heliyon 6, e05675 (2020).
pubmed: 33319114
pmcid: 7726666
doi: 10.1016/j.heliyon.2020.e05675
Gozel, M. G. et al. Recommended precaution procedures protect healthcare workers from Crimean-Congo hemorrhagic fever virus. Int. J. Infect. Dis. 17, e1046–e1050 (2013).
pubmed: 23816412
doi: 10.1016/j.ijid.2013.05.005
Pavel, S. T. I., Yetiskin, H., Kalkan, A. & Ozdarendeli, A. Evaluation of the cell culture based and the mouse brain derived inactivated vaccines against Crimean-Congo hemorrhagic fever virus in transiently immune-suppressed (IS) mouse model. PLoS Negl. Trop. Dis. 14, e0008834 (2020).
pubmed: 33226988
pmcid: 7721194
doi: 10.1371/journal.pntd.0008834
Kortekaas, J. et al. Crimean-Congo hemorrhagic fever virus subunit vaccines induce high levels of neutralizing antibodies but no protection in STAT1 knockout mice. Vector Borne Zoonotic Dis. 15, 759–764 (2015).
pubmed: 26684523
pmcid: 7643766
doi: 10.1089/vbz.2015.1855
Scholte, F. E. M. et al. Single-dose replicon particle vaccine provides complete protection against Crimean-Congo hemorrhagic fever virus in mice. Emerg. Microbes Infect. 8, 575–578 (2019).
pubmed: 30947619
pmcid: 6455139
doi: 10.1080/22221751.2019.1601030
Hinkula, J. et al. Immunization with DNA plasmids coding for Crimean-Congo hemorrhagic fever virus capsid and envelope proteins and/or virus-like particles induces protection and survival in challenged mice. J. Virol. 91, e02076-16 (2017).
pubmed: 28250124
pmcid: 5411611
doi: 10.1128/JVI.02076-16
Rodriguez, S. E. et al. Vesicular stomatitis virus-based vaccine protects mice against Crimean-Congo hemorrhagic fever. Sci. Rep. 9, 7755 (2019).
pubmed: 31123310
pmcid: 6533279
doi: 10.1038/s41598-019-44210-6
Buttigieg, K. R. et al. A novel vaccine against Crimean-Congo haemorrhagic fever protects 100% of animals against lethal challenge in a mouse model. PLoS ONE 9, e91516 (2014).
pubmed: 24621656
pmcid: 3951450
doi: 10.1371/journal.pone.0091516
Zivcec, M., Safronetz, D., Scott, D. P., Robertson, S. & Feldmann, H. Nucleocapsid protein-based vaccine provides protection in mice against lethal Crimean-Congo hemorrhagic fever virus challenge. PLoS Negl. Trop. Dis. 12, e0006628 (2018).
pubmed: 30011277
pmcid: 6062107
doi: 10.1371/journal.pntd.0006628
Garrison, A. R. et al. A DNA vaccine for Crimean-Congo hemorrhagic fever protects against disease and death in two lethal mouse models. PLoS Negl. Trop. Dis. 11, e0005908 (2017).
pubmed: 28922426
pmcid: 5619839
doi: 10.1371/journal.pntd.0005908
Hawman, D. W. et al. A DNA-based vaccine protects against Crimean-Congo haemorrhagic fever virus disease in a cynomolgus macaque model. Nat. Microbiol. 6, 187–195 (2021).
pubmed: 33257849
doi: 10.1038/s41564-020-00815-6
Appelberg, S. et al. Nucleoside-modified mRNA vaccines protect IFNAR
doi: 10.1128/jvi.01568-21
pubmed: 34817199
Tipih, T., Heise, M. & Burt, F. J. Immunogenicity of a DNA-based Sindbis replicon expressing Crimean–Congo hemorrhagic fever virus nucleoprotein. Vaccines https://doi.org/10.3390/vaccines9121491 (2021).
doi: 10.3390/vaccines9121491
pubmed: 34960237
pmcid: 8703447
Leventhal, S. S. et al. Replicating RNA vaccination elicits an unexpected immune response that efficiently protects mice against lethal Crimean-Congo hemorrhagic fever virus challenge. eBioMedicine 82, 104188 (2022).
pubmed: 35907368
pmcid: 9335360
doi: 10.1016/j.ebiom.2022.104188
Dowall, S. D., Carroll, M. W. & Hewson, R. Development of vaccines against Crimean-Congo haemorrhagic fever virus. Vaccine 35, 6015–6023 (2017).
pubmed: 28687403
pmcid: 5637709
doi: 10.1016/j.vaccine.2017.05.031
Suschak, J. J. et al. A CCHFV DNA vaccine protects against heterologous challenge and establishes GP38 as immunorelevant in mice. npj Vaccines 6, 31 (2021).
pubmed: 33654101
pmcid: 7925670
doi: 10.1038/s41541-021-00293-9
Hawman, D. W. et al. Accelerated DNA vaccine regimen provides protection against Crimean-Congo hemorrhagic fever virus challenge in a macaque model. Mol. Ther. https://doi.org/10.1016/j.ymthe.2022.09.016 (2023).
doi: 10.1016/j.ymthe.2022.09.016
pubmed: 36184852
Dowall, S. D. et al. Protective effects of a modified vaccinia Ankara-based vaccine candidate against Crimean-Congo haemorrhagic fever virus require both cellular and humoral responses. PLoS ONE 11, e0156637 (2016).
pubmed: 27272940
pmcid: 4896484
doi: 10.1371/journal.pone.0156637
Dowall, S. D. et al. A Crimean-Congo hemorrhagic fever (CCHF) viral vaccine expressing nucleoprotein is immunogenic but fails to confer protection against lethal disease. Hum. Vaccin. Immunother. 12, 519–527 (2016).
pubmed: 26309231
doi: 10.1080/21645515.2015.1078045
Gruber, C. E. M. et al. Geographical variability affects CCHFV detection by RT-PCR: a tool for in-silico evaluation of molecular assays. Viruses https://doi.org/10.3390/v11100953 (2019).
doi: 10.3390/v11100953
pubmed: 31623214
pmcid: 6833031
Shrivastava, N. et al. Development of double antibody sandwich ELISA as potential diagnostic tool for rapid detection of Crimean-Congo hemorrhagic fever virus. Sci. Rep. 11, 14699 (2021).
pubmed: 34282163
pmcid: 8289837
doi: 10.1038/s41598-021-93319-0